3rd Quarter - Report

ARENTFOX SCHIFF LLP for ORGANOGENESIS INC.

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing product Physician Fee Schedule regulations regarding reimbursement for chronic wound healing product

LobbyistCovered position, as disclosed
PATRICE HOWARD New —
DAN RENBERG —
OLIVER SPURGEON III —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products S. 4348 (FDASLA Act of 2022), regarding Food and Drug Administration policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding Food and Drug Administration policy on chronic wound healing products

LobbyistCovered position, as disclosed
DAN RENBERG —

Bills named: H.R. 6000 (117th), H.R. 7667 (117th), S. 4348 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.